Analyzing Bio-Reference Laboratories (BRLI) and RadNet (RDNT)
Bio-Reference Laboratories (NASDAQ: BRLI) and RadNet (NASDAQ:RDNT) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.
This is a summary of recent ratings and recommmendations for Bio-Reference Laboratories and RadNet, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
RadNet has a consensus target price of $8.00, suggesting a potential downside of 4.19%. Given RadNet’s higher probable upside, analysts clearly believe RadNet is more favorable than Bio-Reference Laboratories.
This table compares Bio-Reference Laboratories and RadNet’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Bio-Reference Laboratories and RadNet’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|RadNet||$908.61 million||0.43||$118.35 million||$0.20||41.75|
RadNet has higher revenue and earnings than Bio-Reference Laboratories.
Insider and Institutional Ownership
46.0% of RadNet shares are owned by institutional investors. 9.4% of RadNet shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
RadNet beats Bio-Reference Laboratories on 6 of the 8 factors compared between the two stocks.
About Bio-Reference Laboratories
Bio-Reference Laboratories, Inc. is a clinical testing laboratory, which offers testing, information and related services to physician offices, clinics, hospitals, employers and governmental units. The Company offers a range of laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases. It is focused on esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health and correctional health care. It offers a list of chemical diagnostic tests, including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis, toxicology and other tissue analysis. It operates a clinical knowledge management service through its PSIMedica business unit. It also operates a Web-based connectivity portal solution for laboratories and physicians through its CareEvolve subsidiary. Its laboratory testing business consists of routine testing and esoteric testing.
RadNet, Inc. is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. As of December 31, 2016, the Company had in operation 257 MRI systems, 157 CT systems, 47 PET or combination PET/CT systems, 48 nuclear medicine systems, 479 X-ray systems, 279 mammography systems, 551 ultrasound systems and 104 fluoroscopy systems.
Receive News & Stock Ratings for Bio-Reference Laboratories Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Reference Laboratories Inc and related stocks with our FREE daily email newsletter.